PE20030943A1 - B3-ADRENERGIC RECEPTOR AGONISTS - Google Patents

B3-ADRENERGIC RECEPTOR AGONISTS

Info

Publication number
PE20030943A1
PE20030943A1 PE2003000180A PE2003000180A PE20030943A1 PE 20030943 A1 PE20030943 A1 PE 20030943A1 PE 2003000180 A PE2003000180 A PE 2003000180A PE 2003000180 A PE2003000180 A PE 2003000180A PE 20030943 A1 PE20030943 A1 PE 20030943A1
Authority
PE
Peru
Prior art keywords
phenyl
oxazol
hydroxy
amino
alkyl
Prior art date
Application number
PE2003000180A
Other languages
Spanish (es)
Inventor
Bradley Paul Morgan
Jennifer Anne Lafontaine
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20030943A1 publication Critical patent/PE20030943A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

SE REFIERE A COMPUESTOS HETEROCICLICOS AGONISTAS DEL RECEPTOR ß-ADRENERGICO DE FORMULA I DONDE Ar ES FENILO, HETEROCICLICO AROMATICO O NO CON 1 A 4 HETEROATOMOS DE O, S, N; R1 Y R2 SON H, OH, HALOGENO, ENTRE OTROS; R3 Y R4 SON H, ALQUILO C1-C6; R5 ES H, ALQUILO C1-C6; R6 Y R7 SON H, HALOGENO, ALQUILO C1-C6; R8 ES -CONR1bR2b, -SOR1b, -SO2R1b, ENTRE OTROS; X ES -O-, -NH-, CH2, ENTRE OTROS; m ES 0-1; HET ES IMIDAZOL, OXAZOL, PIRAZOL ENTRE OTROS; R1b Y R2b SON H, AMINO, AMINOARILO ENTRE OTROS. SON COMPUESTOS PREFERIDOS 2-(4-(4-(2-(2(R)-HIDROXI-2-(6-METILPIRIDIN-3-IL)ETIL-AMINO)ETOXI}FENIL)OXAZOL-2-IL)-N,N-DIMETILACETAMIDA, 2-(4-{4-(2-(2(R)-HIDROXI-2-PIRIDIN-3-ILETILAMINO)-ETOXI]FENIL}OXAZOL-2-IL)-N,N-DIMETILACETAMIDA, N,N-DIETIL-2-(4-{4-(2-(2(R)-HIDROXI-2-PIRIDIN-3-ILETIL-AMINO)ETOXI]FENIL})OXAZOL-2-IL)ACETAMIDA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA EN LA QUE EL OTRO AGENTE FARMACEUTICO SE SELECCIONA DE INHIBIDOR DE LA SECRECION DE APOLIPOPROTEINA-B/PROTEINA DE TRANSFERENCIA DE TRIGLICERIDOS, UN AGONISTA DE COLECISTOQUININA-A, UN AGONISTA DE MCR-4, UN ANTAGONISTA DEL RECEPTOR DE CANNABINOIDES ENTRE OTROS. LA COMPOSICION PRESENTA ACTIVIDAD HIPOGLICEMICA Y ES UTIL PARA EL TRATAMIENTO DE LA OBESIDADREFERS TO AGONIST HETEROCYCLIC COMPOUNDS OF THE ß-ADRENERGIC RECEPTOR OF FORMULA I WHERE Ar IS PHENYL, AROMATIC HETEROCYCLIC OR NOT WITH 1 TO 4 O, S, N HETEROATOMS; R1 AND R2 ARE H, OH, HALOGEN, AMONG OTHERS; R3 AND R4 ARE H, C1-C6 ALKYL; R5 IS H, C1-C6 ALKYL; R6 AND R7 ARE H, HALOGEN, C1-C6 ALKYL; R8 IS -CONR1bR2b, -SOR1b, -SO2R1b, AMONG OTHERS; X IS -O-, -NH-, CH2, AMONG OTHERS; m IS 0-1; HET IS IMIDAZOLE, OXAZOLE, PIRAZOLE AMONG OTHERS; R1b AND R2b ARE H, AMINO, AMINOARILO AMONG OTHERS. PREFERRED COMPOUNDS ARE 2- (4- (4- (2- (2 (R) -HYDROXY-2- (6-METHYLPYRIDIN-3-IL) ETHYL-AMINO) ETHOXY} PHENYL) OXAZOL-2-IL) -N, N-DIMETHYLACETAMIDE, 2- (4- {4- (2- (2 (R) -HYDROXY-2-PYRIDIN-3-YLETHYLAMINE) -ETOXY] PHENYL} OXAZOL-2-IL) -N, N-DIMETHYLACETAMIDE, N , N-DIETHYL-2- (4- {4- (2- (2 (R) -HYDROXY-2-PYRIDIN-3-ILETHYL-AMINO) ETOXY] PHENYL}) OXAZOL-2-IL) ACETAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION IN WHICH THE OTHER PHARMACEUTICAL AGENT IS SELECTED AS AN INHIBITOR OF THE SECRETION OF APOLIPOPROTEIN-B / TRIGLYCERID TRANSFER PROTEIN, A CHOLECYSTOQUININE AGONIST, AN ANCIENT-A RECORD AGONIST, AN ANCHRONYST 4 ANCHRONIST OF CANNABINOIDS AMONG OTHERS. THE COMPOSITION PRESENTS HYPOGLYCEMIC ACTIVITY AND IS USEFUL FOR THE TREATMENT OF OBESITY

PE2003000180A 2002-02-27 2003-02-24 B3-ADRENERGIC RECEPTOR AGONISTS PE20030943A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36025102P 2002-02-27 2002-02-27

Publications (1)

Publication Number Publication Date
PE20030943A1 true PE20030943A1 (en) 2003-11-08

Family

ID=27766207

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2003000180A PE20030943A1 (en) 2002-02-27 2003-02-24 B3-ADRENERGIC RECEPTOR AGONISTS

Country Status (13)

Country Link
EP (1) EP1485379A1 (en)
JP (1) JP2005518448A (en)
AU (1) AU2003248356A1 (en)
BR (1) BR0308070A (en)
CA (1) CA2476316A1 (en)
DO (1) DOP2003000587A (en)
GT (1) GT200300043A (en)
MX (1) MXPA04007127A (en)
PA (1) PA8567701A1 (en)
PE (1) PE20030943A1 (en)
TW (1) TW200408637A (en)
UY (1) UY27680A1 (en)
WO (1) WO2003072572A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002085297A2 (en) 2001-04-24 2002-10-31 East Carolina University Compositions & formulations with a non-glucocorticoid steroid &/or a ubiquinone & kit for treatment of respiratory & lung disease
US7405207B2 (en) 2002-06-17 2008-07-29 Epigenesis Pharmaceuticals, Inc. Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereof
GB0324654D0 (en) * 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
JP4618250B2 (en) * 2003-12-23 2011-01-26 アステラス製薬株式会社 Amino alcohol derivative
DE102004021779A1 (en) * 2004-04-30 2005-11-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg New beta-agonists, process for their preparation and their use as medicines
JP5173190B2 (en) 2004-08-25 2013-03-27 武田薬品工業株式会社 Preventive and therapeutic agent for stress urinary incontinence and screening method thereof
PE20091825A1 (en) 2008-04-04 2009-12-04 Merck & Co Inc HYDROXIMETHYL PYRROLIDINES AS AGONISTS OF THE BETA 3 ADRENERGIC RECEPTOR
EP2771006B1 (en) 2011-10-27 2016-05-25 Merck Sharp & Dohme Corp. Process for making beta 3 angonists and intermediates
EP2770996B1 (en) 2011-10-27 2016-09-28 Merck Sharp & Dohme Corp. Process for making beta 3 agonists and intermediates
HUE045260T2 (en) 2013-03-15 2019-12-30 Merck Sharp & Dohme Process for preparing beta 3 agonists and intermediates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO179246C (en) * 1991-11-20 1996-09-04 Sankyo Co Aromatic amino-alcohol derivatives and intermediates for their preparation
KR100327273B1 (en) * 1994-04-08 2002-05-10 고사이 아끼오 Ether compound, use thereof, and intermediate for producing the compound
JPH11504649A (en) * 1995-05-10 1999-04-27 ファイザー・インコーポレーテッド β-adrenergic agonist
GB9812709D0 (en) * 1998-06-13 1998-08-12 Glaxo Group Ltd Chemical compounds
WO2002032897A1 (en) * 2000-10-20 2002-04-25 Pfizer Products Inc. Alpha-aryl ethanolamines and their use as beta-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
GT200300043A (en) 2003-09-22
WO2003072572A1 (en) 2003-09-04
UY27680A1 (en) 2003-10-31
AU2003248356A1 (en) 2003-09-09
MXPA04007127A (en) 2005-07-05
DOP2003000587A (en) 2003-08-30
CA2476316A1 (en) 2003-09-04
BR0308070A (en) 2004-12-21
PA8567701A1 (en) 2003-11-12
TW200408637A (en) 2004-06-01
EP1485379A1 (en) 2004-12-15
JP2005518448A (en) 2005-06-23
WO2003072572A8 (en) 2004-01-29

Similar Documents

Publication Publication Date Title
PE20090434A1 (en) SULFONIL AMIDE DERIVATIVES AS KINASE INHIBITORS
PE20090837A1 (en) NEW CHEMICALS
PE20110308A1 (en) 1,2,5-OXADIAZOLES AS INHIBITORS OF INDOLAMINE 2,3-DIOXYGENASE
PE20030943A1 (en) B3-ADRENERGIC RECEPTOR AGONISTS
PE20141375A1 (en) GLUCOKINASE ACTIVATORS
PE20090884A1 (en) INDOL COMPOUNDS AS GLUCOKINASE ACTIVATORS
PE20030547A1 (en) IMIDAZOLE DERIVATIVES FOR THE TREATMENT OF OBESITY
PE20110341A1 (en) HETEROCYCLIC COMPOUNDS THAT MODULATE THE ACTIVITY OF STEROIL-CoA-DESATURASE
PE20120136A1 (en) COMPOUNDS DERIVED FROM N-ACILSULFONAMIDES AS INHIBITORS OF BCL-2
PE20071034A1 (en) HETEROCYCLIC COMPOUNDS AS CETP INHIBITORS
PE20010406A1 (en) 2- {2-METHYL-4 [({4-METHYL-2 [4- (TRIFLUORomethyl) PHENYL] -1,3-THIAZOL-5-IL} METHYL) SULPHANIL] PHENOXY} ACETIC ACID AS hPPARd AGONIST
PE20071022A1 (en) COMPOUNDS DERIVED FROM DIBENCILAMINE AS INHIBITORS OF CHOLESTERYL ESTER TRANSFER PROTEIN (CEPT)
PE20051146A1 (en) HETEROCYCLIC ANTICITOCIN COMPOUNDS
PE20090423A1 (en) SIRTUIN MODULATING COMPOUNDS
HRP20100326T1 (en) 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
PE20070359A1 (en) PYRIMIDINYLPIRAZOLE INHIBITORS FROM AURORA KINASES
DE602004012858D1 (en) 2-AMINOBENZOTHIAZOLE AS CB1 RECEPTOR INVERSE AGONISTS
DE60204718D1 (en) 3-SUBSTITUTED OXINDOL BETA 3 AGONISTS
PE20090617A1 (en) AMINO-5 - [- 4- (DIFLUOROMETOXI) PHENYL] -5-PHENYLIMIDAZOLONE COMPOUNDS FOR THE INHIBITION OF -SECRETASE
PE20090606A1 (en) NEW CATEPSIN C INHIBITORS AND USE
PE20040775A1 (en) INDEOL DERIVATIVES AS ß2-ADRENORECEPTOR AGONISTS
PE20071062A1 (en) PHENICOL CARBONATE ANTIBIOTICS
PE20081351A1 (en) QUINAZOLINE DERIVATIVES AS ANTI-CANCER AGENTS
DE602004030470D1 (en) THERAPEUTIC AGENT FOR KERATOCONJUNCTIVE ILLNESSES
PE20020063A1 (en) BIS-ARYLSULFONES AS LIGANDS OF THE 5-HT RECEPTOR

Legal Events

Date Code Title Description
FA Abandonment or withdrawal